Literature DB >> 3662924

An immunological study of otitis media with effusion. Antibodies directed against coagulase-negative staphylococci in the effusion fluid.

T Bunse1, H Hildmann, W Zan, W Opferkuch.   

Abstract

From 14 chronic middle ear effusions (MEEs), 17 strains of coagulase-negative staphylococci (CS) were isolated. We then used an ELISA method to determine the antibody titers against these microorganisms in the corresponding effusion fluids and the blood sera of the patients and compared them to the antibody titers against a group of standard CS. In most cases, no specific immune response could be detected against the infecting CS in either the effusion fluids or in the sera. Our results can be explained by the inability of most CS strains to provoke a specific immune response in chronically inflamed middle ears due to their inhibition by non-specific antibodies, which reach the middle ear cavity by plasma leakage. The non-specific antibody titer against Staphylococcus hominis, however, seems to be much lower than against the other CS species. We found a high specific antibody titer against the infecting CS in the effusion fluid of a single case, but not in the serum. This finding supports the hypothesis that the middle ear mucosa has the ability to produce autonomous, local antibodies which are independent of a systemic immune response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3662924     DOI: 10.1007/bf00458562

Source DB:  PubMed          Journal:  Arch Otorhinolaryngol        ISSN: 0302-9530


  11 in total

1.  The role of coagulase-negative staphylococci in chronic otitis media with effusion.

Authors:  J M Bernstein; D Dryja; E Neter
Journal:  Otolaryngol Head Neck Surg       Date:  1982 Nov-Dec       Impact factor: 3.497

2.  A microbiological study of secretory otitis media using an anaerobic technique.

Authors:  S Edström; H Ejnell; F Jörgensen; A Möller
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1985       Impact factor: 1.538

3.  Effect of extracellular slime substance from Staphylococcus epidermidis on the human cellular immune response.

Authors:  E D Gray; G Peters; M Verstegen; W E Regelmann
Journal:  Lancet       Date:  1984-02-18       Impact factor: 79.321

Review 4.  Immunologic aspects of otitis media with effusion.

Authors:  G Mogi; N Watanabe; S Maeda; T Umehara
Journal:  Acta Otorhinolaryngol Belg       Date:  1983

5.  A bacteriological study of otitis media with effusion. Concurrent coagulase-negative staphylococcal infections in the middle ear.

Authors:  T Bunse; H Hildmann; W Zan; W Opferkuch
Journal:  Arch Otorhinolaryngol       Date:  1987

6.  Local IgA-class antibodies against respiratory viruses in middle ear and nasopharyngeal secretions of children with secretory otitis media.

Authors:  O H Meurman; H K Sarkkinen; H J Puhakka; E S Virolainen; O H Meurman
Journal:  Laryngoscope       Date:  1980-02       Impact factor: 3.325

7.  Plasma component of middle ear effusion evaluated by prekallikrein level.

Authors:  Y Hamaguchi; Y Sakakura; Y Majima; K Ukai; Y Miyoshi
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  1985       Impact factor: 1.538

8.  Bacteria in the middle ear and ear canal of patients with secretory otitis media and with non-inflamed ears.

Authors:  P Sipilä; A M Jokipii; L Jokipii; P Karma
Journal:  Acta Otolaryngol       Date:  1981 Jul-Aug       Impact factor: 1.494

9.  Mucosal immune system: implications in otitis media with effusion.

Authors:  J M Bernstein; P L Ogra
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1980 May-Jun

10.  Antibody coated bacteria in otitis media with effusions.

Authors:  J M Bernstein; D Myers; D Kosinski; R Nisengard; K Wicher
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1980 May-Jun
View more
  1 in total

1.  Mutation in Phex gene predisposes BALB/c-Phex(Hyp-Duk)/Y mice to otitis media.

Authors:  Fengchan Han; Heping Yu; Ping Li; Jiangping Zhang; Cong Tian; Hongbo Li; Qing Yin Zheng
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.